Our Portfolio

Our companies are developing innovative therapeutics for severe diseases and contitions. We are backing great teams with development programs that make a true difference for patients.

AM Pharma

AM-Pharma is a clinical stage biopharmaceutical company developing recombinant human Alkaline Phosphatase (recAP) as a potentially life-saving treatment of acute kidney injury and sepsis.


Alentis Therapeutics

AlentisTherapeutics discovers and develops novel mediacations to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).


NovaGo Therapeutics

NovaGo Therapeutics is a Swiss start-up dedicated to the development of regenerative therapies for diseases of the central nervous system such as stroke and spinal cord injury.



Eyevensys is a private ophthalmology biotech company developing non-viral gene therapies for severe eye diseases using their proprietary ocular electrotransfection platform. This enables steady expression of the therapeutic protein in the eye. The lead program of the company is EYS606, a treatment for chronic non-infectious uveitis. The company has additional programs in retinitis pigmentosa and age-related macular degeneration.